ReviewGene expression2018
Coffee Consumption and Prevention of Cirrhosis: In Support of the Caffeine Hypothesis.
Review in Gene expression, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Nutraceutical Profiles and FTIR Fingerprints of ComorianMetabolites · 2026Article
- Protective Effect of Caffeine and Chlorogenic Acids of Coffee in Liver Disease.Foods (Basel, Switzerland) · 2024Review
- Coffee, adenosine, and the liver.Purinergic signalling · 2024Review
- Caffeine in Hepatocellular Carcinoma: Cellular Assays, Animal Experiments, and Epidemiological Investigation.Journal of inflammation research · 2024Review
- Nutritional and Lifestyle Therapy for NAFLD in People with HIV.Nutrients · 2023Review
- Analysis of Volatile Compounds, Composition, and Thermal Behavior of Coffee Beans According to Variety and Roasting Intensity.Foods (Basel, Switzerland) · 2022Article
- Caffeine in liver diseases: Pharmacology and toxicology.Frontiers in pharmacology · 2022Review
- Can coffee silverskin be a useful tool to fight metabolic syndrome?Frontiers in nutrition · 2022Review
- Review
- cAMP Signaling in Pathobiology of Alcohol Associated Liver Disease.Biomolecules · 2020Review
- Characterization of Arabica and Robusta Coffees by Ion Mobility Sum Spectrum.Sensors (Basel, Switzerland) · 2020Article
- Caffeine inhibits hypoxia-induced renal fibroblast activation by antioxidant mechanism.Cell adhesion & migration · 2019Article
- Current and future pharmacological therapies for managing cirrhosis and its complications.World journal of gastroenterology · 2019Review
- Coffee and liver health: Exploring the protective benefits and mechanisms of coffee and its bioactive compounds in liver disorders.International journal of health sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coffee is acknowledged as the most widely used drug worldwide. Coffee is also a foodstuff, so its use is often used to satisfy dietary urges. When used as a drug, coffee is normally consumed as a stimulant rather than to treat or prevent particular diseases. Recently, coffee consumption has been inversely related to progression of liver fibrosis to cirrhosis and even hepatocellular carcinoma. Experiments in cellular and animal models have provided biological plausibility for coffee as an antifibrotic agent in the liver. A recent article examined one of the key questions regarding the antifibrotic role of coffee-specifically what is the primary antifibrotic agent in coffee? This article briefly reviews the relevant issues with regard to coffee as an antifibrotic agent for patients with chronic liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.